March 1994
Volume 35, Issue 3
Free
Articles  |   March 1994
Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis.
Author Affiliations
  • M C Callegan
    Department of Microbiology, Louisiana State University Medical Center School of Medicine, New Orleans.
  • L S Engel
    Department of Microbiology, Louisiana State University Medical Center School of Medicine, New Orleans.
  • J M Hill
    Department of Microbiology, Louisiana State University Medical Center School of Medicine, New Orleans.
  • R J O'Callaghan
    Department of Microbiology, Louisiana State University Medical Center School of Medicine, New Orleans.
Investigative Ophthalmology & Visual Science March 1994, Vol.35, 1033-1037. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M C Callegan, L S Engel, J M Hill, R J O'Callaghan; Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis.. Invest. Ophthalmol. Vis. Sci. 1994;35(3):1033-1037.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

PURPOSE: To compare the chemotherapeutic efficacies of ciprofloxacin (0.3%) and fortified (1.36%) tobramycin for the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus keratitis during early and late stages of infection. METHODS: Rabbit corneas were intrastromally injected with 10(2) colony-forming units (CFU) of methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). Topical therapy was initiated at either 4 hours postinfection (early stage) or at 10 hours postinfection (late stage). Drops were administered every 15 minutes for 5 hours. Corneal bacterial counts and aqueous humor antibiotic concentrations were determined. RESULTS: Early administration of ciprofloxacin sterilized all MSSA-infected corneas and 83% of MRSA-infected corneas. Late administration of ciprofloxacin reduced the numbers of viable MSSA and MRSA to 3.6 and 3.7 log10 CFU per cornea, respectively, but did not sterilize any corneas. Early administration of fortified (1.36%) tobramycin sterilized all MSSA-infected corneas but none of the MRSA-infected corneas. Late administration of tobramycin reduced the viable MSSA to very low numbers (0.5 and 0.0 log10, respectively) and sterilized 33% of MSSA-infected corneas, but had little effect on MRSA-infected corneas. CONCLUSIONS: Early in infection, ciprofloxacin was highly effective against MSSA and MRSA, whereas tobramycin was effective only against MSSA. During later stages of infection, tobramycin was more effective than ciprofloxacin against MSSA, and neither antibiotic was effective against MRSA. Thus, ciprofloxacin is limited by the time of application and tobramycin is limited by the resistance of the MRSA strain.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×